上海华汇拓

Shanghai Huahuituo Pharmaceutical Technology is a clinical-stage biotechnology company based in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics. Founded in 2018 by Dr. Li Jin, the company focuses on addressing significant unmet medical needs in metabolic diseases and inflammatory conditions. Its lead candidate, HHT101, is a potent and selective URAT1 inhibitor currently in Phase 2 clinical trials for the treatment of hyperuricemia and gout. The company is also advancing HHT120, a selective JAK1 inhibitor, which is in early-stage clinical development for autoimmune diseases such as rheumatoid arthritis. Huahuituo leverages a strategic relationship with HitGen, utilizing advanced DNA-encoded library (DEL) technology to accelerate its drug discovery efforts. The company aims to build a robust pipeline of differentiated medicines to improve patient outcomes globally.